Status:
UNKNOWN
Comparison of Nebulized Budesonide and Intranasal Budesonide Spray in Children With Adenotonsillar Hypertrophy
Lead Sponsor:
Second Xiangya Hospital of Central South University
Conditions:
Snoring
Mouth Breathing
Eligibility:
All Genders
3-10 years
Phase:
PHASE3
Brief Summary
Budesonide is one of the most common drugs uesd in children with adenotonsillar hypertrophy. This study aim to evaluate the efficacy of a short course of budesonide inhalation suspension via transnasa...
Eligibility Criteria
Inclusion
- Children are ≥3 years and ≤10 years, have habitual mouth breathing or snoring, and without current or previous use of any corticosteroids or leukotriene receptor inhibitors within 4 weeks preceding the initial study.
Exclusion
- Children with craniofacial, neuromuscular, syndromic, or defined genetic abnormalities; acute upper respiratory tract infection; whose symptoms are not caused by adenotonsillar hypertrophy; and who have had adenotonsillectomy in the past.
Key Trial Info
Start Date :
April 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2024
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT05325489
Start Date
April 1 2022
End Date
September 1 2024
Last Update
April 22 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Otolaryngology, Second Xiangya Hospital, Central South University
Changsha, Hunan, China, 410011